114 related articles for article (PubMed ID: 20107488)
21. PAX3 is expressed in human melanomas and contributes to tumor cell survival.
Scholl FA; Kamarashev J; Murmann OV; Geertsen R; Dummer R; Schäfer BW
Cancer Res; 2001 Feb; 61(3):823-6. PubMed ID: 11221862
[TBL] [Abstract][Full Text] [Related]
22. POU transcription factors in melanocytes and melanoma.
Besch R; Berking C
Eur J Cell Biol; 2014; 93(1-2):55-60. PubMed ID: 24315688
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathogenesis of cutaneous melanocytic neoplasms.
Ibrahim N; Haluska FG
Annu Rev Pathol; 2009; 4():551-79. PubMed ID: 19400696
[TBL] [Abstract][Full Text] [Related]
24. Absolute quantitative PCR for detection of molecular biomarkers in melanoma patients: a preliminary report.
Vendittelli F; Paolillo C; Autilio C; Lavieri MM; Silveri SL; Capizzi R; Capoluongo E
Clin Chim Acta; 2015 Apr; 444():242-9. PubMed ID: 25727516
[TBL] [Abstract][Full Text] [Related]
25. Melan-A positive dermal cells in malignant melanoma in situ.
Danga ME; Yaar R; Bhawan J
J Cutan Pathol; 2015 Jun; 42(6):388-93. PubMed ID: 25726939
[TBL] [Abstract][Full Text] [Related]
26. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.
Kubic JD; Lui JW; Little EC; Ludvik AE; Konda S; Salgia R; Aplin AE; Lang D
J Biol Chem; 2015 Sep; 290(36):21901-14. PubMed ID: 26205821
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of PAX3 by TGF-beta modulates melanocyte viability.
Yang G; Li Y; Nishimura EK; Xin H; Zhou A; Guo Y; Dong L; Denning MF; Nickoloff BJ; Cui R
Mol Cell; 2008 Nov; 32(4):554-63. PubMed ID: 19026785
[TBL] [Abstract][Full Text] [Related]
28. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
29. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
30. New prognostic factors of cutaneous melanoma: a review of the literature.
Li N; Mangini J; Bhawan J
J Cutan Pathol; 2002 Jul; 29(6):324-40. PubMed ID: 12135463
[No Abstract] [Full Text] [Related]
31. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
32. PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
Chang B; Pang LJ; Qi Y; Liu CX; Cao Y; Li HA; Hu WH; Jiang JF; Zhang WJ; Li F
Int J Surg Pathol; 2009 Feb; 17(1):6-15. PubMed ID: 18988640
[TBL] [Abstract][Full Text] [Related]
33. Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma.
Strömberg S; Agnarsdóttir M; Magnusson K; Rexhepaj E; Bolander A; Lundberg E; Asplund A; Ryan D; Rafferty M; Gallagher WM; Uhlen M; Bergqvist M; Ponten F
J Proteome Res; 2009 Apr; 8(4):1639-46. PubMed ID: 19714869
[TBL] [Abstract][Full Text] [Related]
34. Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions.
Cesinaro AM; Natoli C; Grassadonia A; Tinari N; Iacobelli S; Trentini GP
J Invest Dermatol; 2002 Jul; 119(1):187-90. PubMed ID: 12164944
[No Abstract] [Full Text] [Related]
35. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes.
Tatzel J; Poser I; Schroeder J; Bosserhoff AK
Pigment Cell Res; 2005 Apr; 18(2):92-101. PubMed ID: 15760338
[TBL] [Abstract][Full Text] [Related]
36. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):506-10. PubMed ID: 23197006
[TBL] [Abstract][Full Text] [Related]
37. MITF pathway mutations in melanoma.
Yokoyama S; Salma N; Fisher DE
Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
[No Abstract] [Full Text] [Related]
38. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
39. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
40. Melanoma-associated expression of transforming growth factor-beta isoforms.
Van Belle P; Rodeck U; Nuamah I; Halpern AC; Elder DE
Am J Pathol; 1996 Jun; 148(6):1887-94. PubMed ID: 8669474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
